Heterogeneity Diffusion Imaging of gliomas: Initial experience and validation.
<h4>Objectives</h4>Primary brain tumors are composed of tumor cells, neural/glial tissues, edema, and vasculature tissue. Conventional MRI has a limited ability to evaluate heterogeneous tumor pathologies. We developed a novel diffusion MRI-based method-Heterogeneity Diffusion Imaging (H...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0225093 |
id |
doaj-d5c24f2c95604db298f893f453a46353 |
---|---|
record_format |
Article |
spelling |
doaj-d5c24f2c95604db298f893f453a463532021-03-04T11:20:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-011411e022509310.1371/journal.pone.0225093Heterogeneity Diffusion Imaging of gliomas: Initial experience and validation.Qing WangGloria J Guzmán Pérez-CarrilloMaria Rosana PonisioPamela LaMontagneSonika DahiyaDaniel S MarcusMikhail MilchenkoJoshua ShimonyJingxia LiuGengsheng ChenAmber SalterParinaz MassoumzadehMichelle M Miller-ThomasKeith M RichJonathan McConathyTammie L S BenzingerYong Wang<h4>Objectives</h4>Primary brain tumors are composed of tumor cells, neural/glial tissues, edema, and vasculature tissue. Conventional MRI has a limited ability to evaluate heterogeneous tumor pathologies. We developed a novel diffusion MRI-based method-Heterogeneity Diffusion Imaging (HDI)-to simultaneously detect and characterize multiple tumor pathologies and capillary blood perfusion using a single diffusion MRI scan.<h4>Methods</h4>Seven adult patients with primary brain tumors underwent standard-of-care MRI protocols and HDI protocol before planned surgical resection and/or stereotactic biopsy. Twelve tumor sampling sites were identified using a neuronavigational system and recorded for imaging data quantification. Metrics from both protocols were compared between World Health Organization (WHO) II and III tumor groups. Cerebral blood volume (CBV) derived from dynamic susceptibility contrast (DSC) perfusion imaging was also compared with the HDI-derived perfusion fraction.<h4>Results</h4>The conventional apparent diffusion coefficient did not identify differences between WHO II and III tumor groups. HDI-derived slow hindered diffusion fraction was significantly elevated in the WHO III group as compared with the WHO II group. There was a non-significantly increasing trend of HDI-derived tumor cellularity fraction in the WHO III group, and both HDI-derived perfusion fraction and DSC-derived CBV were found to be significantly higher in the WHO III group. Both HDI-derived perfusion fraction and slow hindered diffusion fraction strongly correlated with DSC-derived CBV. Neither HDI-derived cellularity fraction nor HDI-derived fast hindered diffusion fraction correlated with DSC-derived CBV.<h4>Conclusions</h4>Conventional apparent diffusion coefficient, which measures averaged pathology properties of brain tumors, has compromised accuracy and specificity. HDI holds great promise to accurately separate and quantify the tumor cell fraction, the tumor cell packing density, edema, and capillary blood perfusion, thereby leading to an improved microenvironment characterization of primary brain tumors. Larger studies will further establish HDI's clinical value and use for facilitating biopsy planning, treatment evaluation, and noninvasive tumor grading.https://doi.org/10.1371/journal.pone.0225093 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Qing Wang Gloria J Guzmán Pérez-Carrillo Maria Rosana Ponisio Pamela LaMontagne Sonika Dahiya Daniel S Marcus Mikhail Milchenko Joshua Shimony Jingxia Liu Gengsheng Chen Amber Salter Parinaz Massoumzadeh Michelle M Miller-Thomas Keith M Rich Jonathan McConathy Tammie L S Benzinger Yong Wang |
spellingShingle |
Qing Wang Gloria J Guzmán Pérez-Carrillo Maria Rosana Ponisio Pamela LaMontagne Sonika Dahiya Daniel S Marcus Mikhail Milchenko Joshua Shimony Jingxia Liu Gengsheng Chen Amber Salter Parinaz Massoumzadeh Michelle M Miller-Thomas Keith M Rich Jonathan McConathy Tammie L S Benzinger Yong Wang Heterogeneity Diffusion Imaging of gliomas: Initial experience and validation. PLoS ONE |
author_facet |
Qing Wang Gloria J Guzmán Pérez-Carrillo Maria Rosana Ponisio Pamela LaMontagne Sonika Dahiya Daniel S Marcus Mikhail Milchenko Joshua Shimony Jingxia Liu Gengsheng Chen Amber Salter Parinaz Massoumzadeh Michelle M Miller-Thomas Keith M Rich Jonathan McConathy Tammie L S Benzinger Yong Wang |
author_sort |
Qing Wang |
title |
Heterogeneity Diffusion Imaging of gliomas: Initial experience and validation. |
title_short |
Heterogeneity Diffusion Imaging of gliomas: Initial experience and validation. |
title_full |
Heterogeneity Diffusion Imaging of gliomas: Initial experience and validation. |
title_fullStr |
Heterogeneity Diffusion Imaging of gliomas: Initial experience and validation. |
title_full_unstemmed |
Heterogeneity Diffusion Imaging of gliomas: Initial experience and validation. |
title_sort |
heterogeneity diffusion imaging of gliomas: initial experience and validation. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2019-01-01 |
description |
<h4>Objectives</h4>Primary brain tumors are composed of tumor cells, neural/glial tissues, edema, and vasculature tissue. Conventional MRI has a limited ability to evaluate heterogeneous tumor pathologies. We developed a novel diffusion MRI-based method-Heterogeneity Diffusion Imaging (HDI)-to simultaneously detect and characterize multiple tumor pathologies and capillary blood perfusion using a single diffusion MRI scan.<h4>Methods</h4>Seven adult patients with primary brain tumors underwent standard-of-care MRI protocols and HDI protocol before planned surgical resection and/or stereotactic biopsy. Twelve tumor sampling sites were identified using a neuronavigational system and recorded for imaging data quantification. Metrics from both protocols were compared between World Health Organization (WHO) II and III tumor groups. Cerebral blood volume (CBV) derived from dynamic susceptibility contrast (DSC) perfusion imaging was also compared with the HDI-derived perfusion fraction.<h4>Results</h4>The conventional apparent diffusion coefficient did not identify differences between WHO II and III tumor groups. HDI-derived slow hindered diffusion fraction was significantly elevated in the WHO III group as compared with the WHO II group. There was a non-significantly increasing trend of HDI-derived tumor cellularity fraction in the WHO III group, and both HDI-derived perfusion fraction and DSC-derived CBV were found to be significantly higher in the WHO III group. Both HDI-derived perfusion fraction and slow hindered diffusion fraction strongly correlated with DSC-derived CBV. Neither HDI-derived cellularity fraction nor HDI-derived fast hindered diffusion fraction correlated with DSC-derived CBV.<h4>Conclusions</h4>Conventional apparent diffusion coefficient, which measures averaged pathology properties of brain tumors, has compromised accuracy and specificity. HDI holds great promise to accurately separate and quantify the tumor cell fraction, the tumor cell packing density, edema, and capillary blood perfusion, thereby leading to an improved microenvironment characterization of primary brain tumors. Larger studies will further establish HDI's clinical value and use for facilitating biopsy planning, treatment evaluation, and noninvasive tumor grading. |
url |
https://doi.org/10.1371/journal.pone.0225093 |
work_keys_str_mv |
AT qingwang heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT gloriajguzmanperezcarrillo heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT mariarosanaponisio heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT pamelalamontagne heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT sonikadahiya heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT danielsmarcus heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT mikhailmilchenko heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT joshuashimony heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT jingxialiu heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT gengshengchen heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT ambersalter heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT parinazmassoumzadeh heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT michellemmillerthomas heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT keithmrich heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT jonathanmcconathy heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT tammielsbenzinger heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation AT yongwang heterogeneitydiffusionimagingofgliomasinitialexperienceandvalidation |
_version_ |
1714803850492248064 |